UROMONITOR | Non-Invasive Surveillance of Bladder Cancer

Non-Invasive Surveillance

of Bladder Cancer

UROMONITOR is CE certified.

"Several new urinary biomarkers, such as Uromonitor, are very accurate to rule out NMIBC recurrence, and can be used to replace (part of ) invasive cystoscopy procedures."

UROMONITOR | Non-Invasive Surveillance of Bladder Cancer

Benefits

Patients
at Risk

Urology Bladder cancer Patients at risk

Patients undergoing surveillance of bladder cancer, who express the need for less invasive detection methods, Uromonitor offers a totally non-invasive test that is performed in a convenient urine sample.

Urologists

Urologists

Urologist Bladder Cancer UROMONITOR

For the Urologists who need more accurate ancillary tests to monitor bladder cancer recurrence, Uromonitor provides an in vitro diagnosis test with a close to 100% specificity for bladder cancer and an evenly high sensitivity that is irrespective of tumor grade (unlike cytology).

Solution

A Reliable and Convenient NON-INVASIVE solution, based on a new patented urine test for FGFR3 and Tert promoter mutations, which have shown to be highly sensitive and SPECIFIC in detecting recurrence of bladder cancer.

This test can be performed adjunct to cystoscopy, reduce the associated discomfort for patients and improve their quality of life, besides reducing the economic impact of extensive surveillance.

UROMONITOR PACKAGE

Studies have shown UROMONITOR lowers medical costs by 50%.

Test Features

Easy, with no specific equipment needed

A urine filtration kit is made available free of charge and filters are sent at room temperature to Uromonitor Lab where the test is run and results are delivered in 5 working days.

Validated in Clinical Studies

Studies in over 400 samples from eligible patients under surveillance for bladder cancer, the biomarkers have demonstrated to be highly sensitive and specific (> 97,3% sensitivity and 100% specificity).

Proprietary

The test is covered by an International-scope PCT Patent Application protecting the method, compositions and the probes used.

Ultrasensitive

Capable of detecting from 7 abnormal molecules per 1000 normal.

Non-invasive

Based on a simple urine analysis avoiding the recurrent cystoscopies.

Research, Validation, Team and Testing Facilities

Research & Validation

Research

ipatimup - Instituto de Patologia e Imunologia Molecular da Universidade do Porto

The test was developed by researchers from IPATIMUP, a renowned cancer research center (www.ipatimup.pt) at Oporto, Portugal. Uromonitor’s team of researchers are experts in biomarkers in the cancer biology and molecular genetics field.

Clinical Studies

lisbon instituto portugues de oncologia francisco gentil EPE center

The Uromonitor test was validated with clinical samples from bladder cancer patients followed-up at the Portuguese Institute of Oncology. A showcase study involving the leading expert in the field Dr Fred Witjes is now undergoing at an International reference center in Urology (Radboud University Nijmegen Medical Centre – The Netherlands).

Team & Testing Facilities

Team

UROMONITOR | Non-Invasive Surveillance of Bladder Cancer

The test is performed by highly qualified personal that has been involved in performing the Uromonitor test throughout the development and validation phases, thus insuring the accumulated experience to achieve the best results. All aspects of customer relationships are handled by an expedite team of logistics and customer support experts.

Lab Facilities

Instituto de Investigação e Inovação em Saúde da Universidade do Porto

State-of the art Uromonitor Lab facilities at Ipatimup and i3S are used to run the test, in keeping with all laboratory quality standards.

Scientific Publications

Prospective validation of urine based FGFR screening by Uromonitor within the real-world clinicopathological register trial BRIDGister

The objective of the present study was to prospectively evaluate FGFR mutation detetion in matched urine and tissue samples from patients suspicious of bladder cancer and undergoing first TURB within the framework of the BRIDGister RealWorld Experience trial. Results: The pilote cohort of the BRIDGister trial consisted of 47 patients (median age: 77, male 65% vs… Read more »

lisbon instituto portugues de oncologia francisco gentil EPE center

VALIDATION OF A NOVEL, SENSITIVE, AND SPECIFIC URINE-BASED TEST FOR RECURRENCE SURVEILLANCE OF PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER IN A COMPREHENSIVE MULTICENTER STUDY

The Uromonitor test was recently validated by the scientific community in a international recognized peer-reviewed journal (Frontiers in Genetics) in a multicentric study comprising more than 300 human samples. Uromonitor presented high sensitivity (74%) and specificity (93%) in the detection of recurrence in patients under Follow-up for Non-Muscle Invasive Bladder Cancer.   The details of… Read more »

Urologist Bladder Cancer UROMONITOR

BIOMARKERS FOR BLADDER CANCER DIAGNOSIS AND SURVEILLANCE: A COMPREHENSIVE REVIEW

Uromonitor test was recognized and considered by the scientific community as an excellent alternative for the non-invasive follow-up of patients previously diagnosed with Non-Muscle Invasive Bladder Cancer in a scientific article that was issue cover in an recognized international journal (Diagnostics). Bladder cancer (BC) ranks as the sixth most prevalent cancer in the world, with… Read more »

TERT PROMOTER MUTATION AS A POTENTIAL PREDICTIVE BIOMARKER IN BCG-TREATED BLADDER CANCER PATIENTS

Recently, investigators described in a scientific publications in a recognized international journal (International Journal of Molecular Sciences), the future possibility of the use of an genetic alterations in TERT gene, included in the Uromonitor test, to be used as a therapy response predictive biomarker in BCG treatment. The details of this study can be found… Read more »

Innovative Technology

Innovation Process

View All Articles Latest News / In The Press

Biomarkers for bladder cancer diagnosis and surveillance: a comprehensive review

Uromonitor test was recognized and considered by the scientific community as an excellent alternative for the non-invasive follow-up of patients previously diagnosed with Non-Muscle Invasive Bladder Cancer in a scientific article that was issue cover in an recognized international journal (Diagnostics). The details of this study can be found at: https://www.mdpi.com/2075-4418/10/1/39/htm

In times of covid19, cancer patients have a new way to avoid delaying diagnostic procedures and surveillance of bladder tumours.

Concerned about the postponement of surveillance procedures and the increased risk of contamination in Hospitals, a team of researchers from Ipatimup and the Institute for Research and Innovation in Health (i3S) validated a new form of bladder cancer surveillance that, from now on, may be carried-out from home. Bladder cancer mainly affects smoking men over… Read more »

Validation of a novel, sensitive, and specific urine-based test for recurrence surveillance of patients with non-muscle-invasive bladder cancer in a comprehensive multicenter study

The Uromonitor test was recently validated by the scientific community in a international recognized peer-reviewed journal (Frontiers in Genetics) in a multicentric study comprising more than 300 human samples. Uromonitor presented high sensitivity (74%) and specificity (93%) in the detection of recurrence in patients under Follow-up for Non-Muscle Invasive Bladder Cancer. The details of this… Read more »

Tert promoter mutation as a potential predictive biomarker in bcg-treated bladder cancer patients

Recently, investigators described in a scientific publications in a recognized international journal (International Journal of Molecular Sciences), the future possibility of the use of an genetic alterations in TERT gene, included in the Uromonitor test, to be used as a therapy response predictive biomarker in BCG treatment. The details of this study can be found… Read more »

Prize entrepreneurs of the EVERIS FOUNDATION

The president of the Everis Foundation, Eugenio Galdón, has awarded the Everis Prize 2015 to Hugo Prazeres for his Uromonitor project, a non-invasive test to detect bladder cancer by using a biomarker in urine samples, whose use avoids performing a cystoscopy, an uncomfortable procedure for the patient and expensive for the Public Health System. Read… Read more »